Californian cardiorenal disease specialist Ardelyx (Nasdaq: ARDX) announced positive results from the Phase III AMPLIFY study on Tuesday, sending shares in the firm up over 70%.
The company is evaluating tenapanor, a novel oral therapy with a unique mechanism of action, for people with chronic kidney disease (CKD) on dialysis.
The study tests a combination of tenapanor and phosphate binders, as an option for people whose hyperphosphatemia has not been controlled with binders alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze